STOCK TITAN

Serina Therapeutics (SER) EPS by Year

SER

Serina Therapeutics lost $1.91 per diluted share in fiscal year 2025. This represents a decrease of 26.5% from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters Serina Therapeutics has filed alongside them.

FY2025 annual
EPS (Diluted) -$1.91
YoY -26.5%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

SER EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-K
EPS (Diluted)-$1.91-26.5%-$1.51-306.8%$0.73-$9.70N/AN/AN/AN/AN/A

SER EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
EPS (Diluted)-$0.55-$0.58-18.4%-$0.31-14.8%-$0.45-446.2%-$0.66-229.4%-$0.49-$0.27$0.13$0.51+363.6%-$5.38-$13.42-41.3%$0.23

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Serina Therapeutics financials

Frequently Asked Questions

What was Serina Therapeutics's diluted earnings per share in fiscal year 2025?

Serina Therapeutics lost $1.91 per diluted share in fiscal year 2025.

How fast is Serina Therapeutics's diluted earnings per share growing?

Serina Therapeutics (SER) diluted earnings per share fell by 26.5% year over year, from -$1.51 to -$1.91 in fiscal year 2025.

What was Serina Therapeutics's diluted earnings per share in the most recent quarter?

Serina Therapeutics (SER) reported -$0.55 in diluted earnings per share in Q2 2026.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Serina Therapeutics (SER) reported on that line in every period on record.